Pathogenetic processes

Pathogenetic processes (PPs) — are major molecular and phenotypic characteristics that determinate cancer as complex evolutionary disease process.


Name ( total associations | neutral | plus | minus )


adhesion ( 51 / 28 /
7
/
16
)
Angiogenesis ( 296 / 153 /
50
/
93
)
Anoikis ( 24 / 13 /
5
/
6
)
Antiapoptosis ( 37 / 20 /
12
/
5
)
Apoptosis ( 1856 / 942 /
592
/
322
)
Autophagy ( 337 / 169 /
75
/
93
)
beta-catenin signaling ( 71 / 36 /
13
/
22
)
cell cycle ( 260 / 136 /
45
/
79
)
cell cycle arrest ( 507 / 257 /
222
/
28
)
Cell growth ( 794 / 401 /
121
/
272
)
Chemoresistance ( 294 / 148 /
57
/
89
)
colony formation ( 523 / 267 /
68
/
188
)
differentiation ( 95 / 48 /
31
/
16
)
DNA repair ( 61 / 31 /
21
/
9
)
EMT ( 927 / 470 /
193
/
264
)
growth ( 222 / 131 /
26
/
65
)
inflammation ( 85 / 43 /
16
/
26
)
Invasion ( 3747 / 1899 /
613
/
1235
)
MET ( 18 / 10 /
8
/
)
Metastasis ( 1159 / 588 /
239
/
332
)
migration ( 2995 / 1513 /
479
/
1003
)
motility ( 205 / 105 /
33
/
67
)
NF-kB signaling ( 191 / 97 /
47
/
47
)
Oxaliplatin ( 2 / 1 /
1
/
)
Oxaliplatin resistance ( 29 / 15 /
7
/
7
)
Paclitaxel resistance ( 67 / 34 /
13
/
20
)
Proliferation ( 4268 / 2154 /
696
/
1418
)
Radioresistance ( 139 / 71 /
26
/
42
)
Senescence ( 69 / 38 /
23
/
8
)
stemness ( 235 / 118 /
53
/
64
)
survival ( 134 / 69 /
23
/
42
)
Tamoxifen resistance ( 21 / 11 /
7
/
3
)
5fluorouracil resistance ( 124 / 71 /
23
/
30
)
AKT signaling ( 299 / 151 /
52
/
96
)
cell viability ( 316 / 162 /
39
/
115
)
cisplatin resistance ( 328 / 165 /
55
/
108
)
doxorubicin resistance ( 77 / 39 /
10
/
28
)
ERK pathway (MAPK pathway) ( 185 / 93 /
30
/
62
)
etoposide ( 7 / 4 /
2
/
1
)
Liver metastasis ( 28 / 16 /
4
/
8
)
G1-S checkpoint ( 7 / 4 /
2
/
1
)
multidrug resistance ( 22 / 12 /
5
/
5
)
RAS signaling pathway ( 8 / 5 /
1
/
2
)
tumor growth ( 830 / 418 /
144
/
268
)
cancer progression ( 16 / 9 /
5
/
2
)
cell cycle progression ( 189 / 96 /
46
/
47
)
Lung metastasis ( 65 / 34 /
14
/
17
)
PI3K signaling ( 97 / 49 /
17
/
31
)
WNT signaling ( 380 / 191 /
88
/
101
)
anchorage-independent growth ( 37 / 19 /
10
/
8
)
Bone metastasis ( 26 / 15 /
3
/
8
)
Castrate Resistance ( 27 / 16 /
9
/
2
)
Hedgehog (Hh) signaling ( 31 / 16 /
5
/
10
)
myeloid differentiation ( 27 / 14 /
7
/
6
)
tumor-stroma interactions ( 3 / 2 /
1
/
)
Adriamycin (Adr) resistance ( 26 / 14 /
3
/
9
)
aerobic glycolysis ( 73 / 37 /
11
/
25
)
docetaxel resistance ( 41 / 22 /
14
/
5
)
epirubicin resistance ( 5 / 3 /
2
/
)
gefitinib resistance ( 32 / 17 /
4
/
11
)
JAK/STAT signaling ( 110 / 56 /
28
/
26
)
mTOR signaling ( 86 / 43 /
9
/
34
)
Necrosis ( 4 / 2 /
1
/
1
)
NOTCH signaling ( 75 / 38 /
19
/
18
)
P38 signaling ( 33 / 17 /
10
/
6
)
poor prognosis ( 46 / 26 /
17
/
3
)
Transformation ( 15 / 12 /
2
/
1
)
tumor progression ( 82 / 42 /
24
/
16
)
Tumorigenesis ( 43 / 22 /
7
/
14
)
unfolded protein response ( 7 / 5 /
1
/
1
)
Vorinostat Resistance ( 6 / 4 /
2
/
)
cytotoxicity ( 2 / 1 /
1
/
)
TGF-beta signaling ( 392 / 219 /
84
/
89
)
Temozolomide (TMZ) resistance ( 36 / 18 /
6
/
12
)
BMP signaling ( 110 / 64 /
13
/
33
)
daunorubicin (DNR) Resistance ( 4 / 2 /
2
/
)
T cell activation ( 3 / 2 /
1
/
)
gemcitabine resistance ( 56 / 28 /
8
/
20
)
genomic instability ( 4 / 2 /
1
/
1
)
Sorafenib resistance ( 28 / 14 /
6
/
8
)
glucose metabolism ( 18 / 9 /
3
/
6
)
BRCAness ( 2 / 1 /
1
/
)
BRAFi resistance ( 4 / 2 /
1
/
1
)
MEKi resistance ( 4 / 2 /
1
/
1
)
immunoevasion ( 26 / 13 /
7
/
6
)
Hippo signaling pathway ( 176 / 88 /
66
/
22
)
fibrosis ( 36 / 18 /
6
/
12
)
MAPK/JNK Signaling Pathway ( 16 / 8 /
5
/
3
)
carboplatin resistance ( 4 / 2 /
1
/
1
)
Hypoxic response ( 10 / 6 /
4
/
)
Taxanes (paclitaxel and docetaxel) resistance ( 14 / 10 /
2
/
2
)
Trastuzumab resistance ( 8 / 4 /
2
/
2
)
TRAIL resistance ( 16 / 8 /
5
/
3
)
Cetuximab resistance ( 20 / 10 /
7
/
3
)
pyroptosis ( 4 / 2 /
1
/
1
)
Sunitinib resistance ( 8 / 4 /
4
/
)
tumor-initiating properties ( 9 / 6 /
/
3
)
ER stress ( 28 / 15 /
/
13
)
cell spreading ( 8 / 6 /
/
2
)
inflammatory monocyte recruitment ( 4 / 3 /
/
1
)
Imatinib resistance ( 12 / 8 /
/
4
)
NK cell cytotoxicity ( 6 / 4 /
/
2
)
Camptothecin resistance ( 3 / 2 /
/
1
)
disease-free survival ( 3 / 2 /
/
1
)
EGFR-TKI resistance ( 4 / 3 /
/
1
)
MTX resistance ( 3 / 2 /
/
1
)
Osteolysis ( 5 / 3 /
/
2
)
gluconeogenesis ( 4 / 2 /
/
2
)
lipogenesis ( 23 / 12 /
/
11
)
Afatinib resistance ( 2 / 1 /
/
1
)
Lapatinib resistance ( 4 / 2 /
/
2
)
Neratinib resistance ( 2 / 1 /
/
1
)
Brain metastasis ( 2 / 1 /
/
1
)
Rapamycin resistance ( 2 / 1 /
/
1
)
BCL2 inhibitors resistance ( 2 / 1 /
/
1
)
branching-morphogenesis ( 1 / 1 /
0
/
0
)
cell polarity ( 1 / 1 /
0
/
0
)
cellular repair of DNA double-strand breaks ( 1 / 1 /
0
/
0
)
chondrogenesis ( 1 / 1 /
0
/
0
)
cyclophosphamide sensitivity ( 1 / 1 /
0
/
0
)
endothelial-mesenchymal transition ( 1 / 1 /
0
/
0
)
erythropoiesis ( 3 / 3 /
0
/
0
)
glycolysis ( 11 / 11 /
0
/
0
)
HCPT (Hydroxycamptothecin) resistantance ( 1 / 1 /
0
/
0
)
Hepatocyte differentation ( 2 / 2 /
0
/
0
)
insulin signaling ( 1 / 1 /
0
/
0
)
macrophage attraction ( 1 / 1 /
0
/
0
)
microtubule-targeting drugs ( 4 / 4 /
0
/
0
)
mitoxantrone (MX) Resistance ( 1 / 1 /
0
/
0
)
neutrophil chemotaxis ( 2 / 2 /
0
/
0
)
recurrence ( 2 / 2 /
0
/
0
)
redox homeostasis ( 3 / 3 /
0
/
0
)
Response to oxidative stress ( 8 / 8 /
0
/
0
)
Response to genotoxic stress ( 2 / 2 /
0
/
0
)
scattering ( 1 / 1 /
0
/
0
)
Tomudex (TDX) resistance ( 1 / 1 /
0
/
0
)
Vinblastine (Velban) resistance ( 1 / 1 /
0
/
0
)